Drug Trial Radar · NCT02689583
A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection
Last checked: Nov 19, 2026Latest source record: Feb 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,000
Planned (sponsor's estimate)
Start
Mar 2016
Primary completion
Mar 2017
Sponsor
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking Union Medical College Hospital; Nanfang Hospital, Southern Medical University; Third Affiliated Hospital of Third Military Medical University; The First Affiliated Hospital with Nanjing Medical University; Centers for Disease Control and Prevention, China; Academy Military Medical Science, China
- First posted
- Feb 24, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Since the discovery of Helicobacter pylori (H. pylori), many studies have been carried out with the goal of improving H. pylori eradication and therapies have changed from single-antibiotic treatments to the current multi-antibiotic treatments. However, the eradication rate of H. pylori is still less than 80%. The reasons for this low eradication rate are likely to be multi-factorial, including the reduced activity of antimicrobial drugs, poor patient compliance or micro-environment in stomach. In this study, to obtain the higher eradication of H. pylori and discover the different mechanism between the current infection and refractory infection of H. pylori, it is necessary to perform a prevalence survey for eradication of H. pylori based on the results from isolation of H. pylori strains, antibiotic susceptibility testing, CYP2C19 gene polymorphism, drug resistance gene sequencing and 16SrRNA sequencing.
Conditions
- Gastritis
- Gastric Ulcer
Interventions
Antibiotic selection based on the antibiotic susceptibility testingBiological
The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.
PPI selection based on the CYP2C19 gene polymorphismGenetic
PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
Probiotics usage based on the 16SrRNA sequencingDietary supplement
Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication ratesTime frame: Three months
- Mutation site of drug resistance geneTime frame: Three months
- The distribution and proportion of microflora in stomachTime frame: Three months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.